- Home
- SBR vs ORIC Comparison
SBR vs ORIC Comparison
Compare SBR & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBR | ORIC |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 861.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SBR | ORIC |
|---|---|---|
| Price | $73.75 | $14.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | 32.1K | ★ 1.7M |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.41% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $65.31 | $7.23 |
| 52 Week High | $84.39 | $14.93 |
Technical Indicators
Market Signals| Indicator | SBR | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 53.14 | 63.17 |
| Support Level | $72.39 | $10.45 |
| Resistance Level | $79.65 | $14.14 |
| Average True Range (ATR) | 1.24 | 0.84 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 87.12 | 83.29 |
Price Performance
Historical ComparisonAbout SBR Sabine Royalty Trust
Sabine Royalty Trust formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.